COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids (Halt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00874029
Recruitment Status : Completed
First Posted : April 2, 2009
Results First Posted : July 3, 2014
Last Update Posted : July 3, 2014
Information provided by (Responsible Party):
Acessa Health, Inc.

Brief Summary:
The purpose of this study is to demonstrate the safety and effectiveness of radiofrequency ablation (RFA) using the Halt System for the treatment of patients with symptomatic uterine fibroids.

Condition or disease Intervention/treatment Phase
Uterine Fibroids Uterine Myomas Device: Halt Procedure Not Applicable

Detailed Description:
In this single-arm study, subjects who have symptomatic uterine fibroids will have laparoscopic surgery in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 137 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Halt System for Laparoscopic Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation
Study Start Date : March 2009
Actual Primary Completion Date : January 2012
Actual Study Completion Date : March 2014

Arm Intervention/treatment
Experimental: Halt Procedure
In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
Device: Halt Procedure
The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
Other Names:
  • Halt
  • Halt2000
  • The Halt System
  • The Halt 2000 System

Primary Outcome Measures :
  1. Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure [ Time Frame: 12 months from Baseline ]
    Change in volume of menstrual blood loss at 12 months post-procedure compared to baseline. Bleeding relief and surgical reintervention were the co-primary endpoints. Bleeding relief success was defined for individual subjects as a ≥ 50% reduction from baseline in menstrual blood loss at 12 months posttreatment. The Primary Full Analysis Set was the primary analysis set for bleeding success rate.

  2. Incidence of Device and Procedure-related Adverse Events Within 12 Months Post-procedure [ Time Frame: 12 months ]
    An adverse event was defined as any untoward medical occurrence in a subject who uses a medical device, regardless of the presumed relationship of the event to the study device. A serious adverse event is defined as an untoward medical occurrence that results in death, is life threatening, requires or prolongs hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. Preexisting conditions (i.e., underlying diseases that were present before the adverse event reporting period began), re-intervention for failure to meet the study endpoints, and pregnancy were not reported as adverse events. All adverse events that occured during the study were recorded on the Adverse Event case report form (CRF). The investigator recorded the adverse event and assessed the relationship of the adverse event to the device and/or procedure; the coding of the events was reviewed by the Clinical Events Committee (CEC).

  3. Surgical Re-Intervention for Menorrhagia at 12 Months Post-treatment [ Time Frame: 12 months from Baseline ]
    Patients who had surgical reintervention for bleeding prior to 12 months follow-up. Surgical reintervention success was defined as no surgical reintervention for menorrhagia within the 12-month posttreatment period.

Secondary Outcome Measures :
  1. Change in Uterine and Fibroid Volume at 12 Months Post-procedure Compared to Pre-procedure (Baseline) as Measured With Contrast-enhanced MRI (Magnetic Resonance Imaging) [ Time Frame: 12 month from Baseline ]
    Evaluate change from baseline in uterine volume and fibroid volume at 12 months post-procedure as measured by contrast-enhanced magnetic resonance imaging (MRI) measurements. Specifically, the outcomes of uterine and fibroid volume changes are expressed as a mean percentage of volume reduction. Treatment with RFA resulted in a reduction from baseline in total uterine and fibroid volume, as assessed by pretreatment and posttreatment MRI, at 3 and 12 months posttreatment.

  2. Change in Fibroid Symptom Severity and Quality of Life Scores at 12 Months Post-procedure as Compared to Pre-procedure (Baseline) Using the Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) Assessment Tool. [ Time Frame: 12 months from Baseline ]

    The Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) assessment tool measures symptom severity and Health related quality of life.

    Symptom Severity (SS) - high scores indicate greater symptoms (bad) and low scores indicate less symptoms (good). Scores range from 0 to 100. Since this outcome measure indicates "change" in symptoms, a negative number indicates a reduction in symptoms and therefore improvement.

    Health Related (HRQL) - high scores indicate better health state. Scores range from 0 to 100. Since this outcome measure indicates "change" in health and quality of life, a positive number indicates and improvement.

  3. Change in Score on Questionnaire - General Health Outcome at 12 Months Post-procedure as Compared to Pre-procedure Using the EQ-5D (a Standardized Instrument for Use as a Measure of Health Outcome) [ Time Frame: 12 months ]
    The EQ-5D is a standardized instrument with scores ranging from 0 to 100, for use as a measure of general health outcome, such as mobility, self-care, usual activities, pain/discomfort and anxiety and depression. An increase in the score post treatment indicates less disease burden.

  4. Overall Subject Treatment Outcome and Satisfaction Using the Overall Treatment Evaluation (OTE) [ Time Frame: 12 months ]
    The Overall Treatment Evaluation Survey refers to whether the patient felt symptoms improved, worsened or remained the same post treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Are premenopausal and ≥ 25 years old
  • Have symptomatic uterine fibroids
  • Have a uterine gestational size ≤14 weeks as determined by pelvic exam
  • Have ≤ 6 (six) treatable fibroids in whom no single fibroid exceeds 7 cm in any diameter as measured by ultrasound or magnetic resonance imaging (MRI). Only Fibroids greater than 1cm in diameter should be treated in this study
  • Have a total uterine fibroid volume that does not exceed 300cc on ultrasound or contrast-enhanced MRI evaluation
  • Have clinical menorrhagia as indicated by menstrual blood loss of ≥160 mL to 500 ml during one baseline cycle or two baseline cycles within three months prior to treatment
  • Have a history of at least 3 months of menorrhagia within the last six months
  • Desire uterine preservation
  • Do not desire current or future childbearing
  • Have a normal coagulation profile international normalized ratio (INR), Platelets, Prothrombin Time, and Partial Thromboplastin Time (PTT)
  • Have had a normal Pap smear within the past 12 months
  • Are practicing non-hormonal or stable hormonal contraception
  • If the woman is not currently taking any hormonal contraceptives, has been off all hormonal contraceptives for a minimum of three months prior to study enrollment, and agrees to continue without change in regimen through the 12 months of follow-up OR
  • If the woman is currently taking hormonal contraceptives, has taken hormonal contraceptives for a minimum of three months prior to study enrollment, and agrees to continue without change in regimen through 12 months of follow up.**

    **Note: Hormonal contraceptive use must be terminated 30 days prior to treatment but should be resumed post-operatively within 60 days post treatment as instructed by the Investigator.

  • Are willing and able to comply with all study tests, procedures, and assessment tools
  • Are willing and able to return for all required follow up visits following study enrollment
  • Must pass a pre-operative health exam (ASA I-III)
  • Are capable of providing informed consent

Exclusion Criteria:

  • Have contraindications for laparoscopic surgery and/or general anesthesia. (Contraindications include anemia, defined as a hemoglobin level under 10 or hematocrit level less than 30.)
  • Have had prior pelvic surgery (with the exception of C-section, tubal ligation, or diagnostic laparoscopy), or are known to have significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus)
  • Have previously undergone endometrial ablation, uterine artery embolization, or uterine artery ligation, or any other uterine-preserving technique for reduction of menstrual bleeding (with the exception of hysteroscopic myomectomy > 1 year ago)
  • Patients requiring elective concomitant procedures
  • Have contraindications for magnetic resonance imaging (MRI)
  • Desire current or future childbearing
  • Are pregnant or lactating
  • Have taken any Gonadotropin-releasing hormone (GnRh) agonist within three months prior to the screening procedures
  • Have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed one month prior to treatment
  • Have dysfunctional uterine bleeding or bleeding between periods
  • Have chronic pelvic pain not due to uterine fibroids
  • Have known or suspected endometriosis
  • Have known or suspected adenomyosis based on Ultrasound or MRI findings
  • Have active or history of pelvic inflammatory disease
  • Have a history of or evidence of gynecologic malignancy or pre-malignancy within the past five years
  • Have had pelvic radiation
  • Have a non-uterine pelvic mass
  • Have a cervical myoma
  • Have one or more pedunculated subserosal fibroids or "type zero" (completely intracavitary) submucous fibroids
  • Are peri-menopausal (defined as women 40 years of age or older with Follicular Stimulating Hormone level of ≥ 25 International Units (IU) or menopausal
  • Are unable to give informed consent
  • In the medical judgment of the investigator should not participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00874029

Layout table for location information
United States, Arizona
Women's Health Research
Phoenix, Arizona, United States, 85015
United States, California
USC Medical Center
Los Angeles, California, United States, 90033
Pasadena Premier Women's Health
Pasadena, California, United States, 91145
Reproductive Science Center
San Ramon, California, United States, 94583
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48034
United States, Missouri
St. Luke's Hospital
Chesterfield, Missouri, United States, 63017
United States, Nevada
Athena Gynecology Medical Group
Reno, Nevada, United States, 89509
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461
United States, Pennsylvania
Magee-Women's Hospital
Pittsburgh, Pennsylvania, United States, 15213
Hospital Universitario Esperanza
Guatemala City, Guatemala, 01010
Hospital Universitario Dr. Jose Eleuterio Gonzalez de la Universidad Autonoma de Nuevo Leon. Facultad de Medicina
Monterrey, Nuevo Leon, Mexico, 64460
Sponsors and Collaborators
Acessa Health, Inc.
Layout table for investigator information
Principal Investigator: Mary Hinckley, MD Reproductive Science Center
Principal Investigator: Micah Harris, MD Women's Health Research
Principal Investigator: Erika Banks, MD Montefiore Medical Center
Principal Investigator: Karen R Abbott, MD Athena Gynecology Medical Group
Principal Investigator: Jay Berman, MD Wayne State University
Principal Investigator: Jose G Garza Leal, MD Hospital Universitario Dr. Jose Eleuterio Gonzalez
Principal Investigator: David Levine, MD St. Johns' Mercy Medical Center
Principal Investigator: Rodolfo Robles Pemueller, MD Universidad Francisco Marroquín
Principal Investigator: Jennifer Israel, MD University of Southern California
Principal Investigator: Richard S Guido, MD Magee-Women's Hospital
Principal Investigator: James Macer, MD Pasadena Premier Women's Health
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Acessa Health, Inc. Identifier: NCT00874029    
Other Study ID Numbers: CP-00-0004
First Posted: April 2, 2009    Key Record Dates
Results First Posted: July 3, 2014
Last Update Posted: July 3, 2014
Last Verified: June 2014
Keywords provided by Acessa Health, Inc.:
Uterine Fibroids
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases